MindWalk Holdings (HYFT)

The company’s core technology is branded HYFT, a patented approach that supports the organisation and interpretation of complex biological information. MindWalk also operates the LensAI platform, which is intended to bring diverse scientific inputs into a common computational framework. By connecting data that is often held in separate systems or analysed in isolation, the platform aims to help researchers identify useful patterns, test hypotheses faster, and move promising ideas toward experimental validation.

MindWalk’s capabilities are positioned for use across several areas of modern biopharma research. These include epitope mapping, which is important in immunology and vaccine research; de novo molecular design, where new biological or chemical candidates are created computationally; in silico vaccine exploration; and large-scale analysis of biologics across different populations. A distinguishing feature of the company’s model is its combination of AI-driven analysis with an integrated wet lab, allowing computational outputs to be tested in a laboratory setting. For investors, HYFT represents exposure to an early-stage intersection of artificial intelligence, biotechnology, and pharmaceutical research infrastructure.